scholarly journals Could Fecal Microbiota Be a Useful Indicator of Serum Cholesterol Levels among Men?

2020 ◽  
Vol 10 (4) ◽  
pp. 175
Author(s):  
HuiJun Chih ◽  
Stuart C. Smith ◽  
Ramon S. Hall ◽  
Stuart K. Johnson
Keyword(s):  
Geometric Mean ◽  
Density Lipoprotein ◽  
Secondary Data ◽  
Fold Increase ◽  
Fecal Microbiota ◽  
Surrogate Markers ◽  
Non Invasive ◽  
Cholesterol Levels ◽  
Total Bacteria ◽  
Clostridial Group

Trepidation with blood tests among men may result in fewer routine screening and examination of their cardiovascular risk factors. Associations between fecal microbiota and serum cholesterols have not been well-established. The aim of this study was to explore such association in order to determine the potential of fecal microbiota as a non-invasive alternate predictor of serum cholesterols. Secondary data from a cross-over trial were analyzed. Associations between fecal microbiota, mainly Bifidobacterium and Clostridial group, of healthy men (n = 16) and their total cholesterols, low and high-density lipoprotein cholesterols (LDL-C and HDL-C) were assessed using generalized estimating equations, adjusted for diet intervention, diet order, frequency of defecation and flatulence level. For every two-fold increase in fecal Bifidobacterium, geometric mean of LDL-C increases by a factor of 1.23 (95% CI: 1.01, 1.49) whilst that of HDL-C increases by a factor of 1.07 (95% CI: 1.03, 1.10). For every two-fold increase in Clostridial group (C. ramosum, C. spiroforme and C. cocleatum), geometric mean of HDL-C decreases by a factor of 1.10 (95% CI: −1.16, −1.03). No association was found between total bacteria and serum cholesterols. Fecal Bifidobacterium spp. and Clostridium spp., are potential non-invasive surrogate markers of men’s serum cholesterols.

scholarly journals Statin prescription among patients with type 2 diabetes in Botswana: findings and implications

2019 ◽  
Author(s):  
Julius Chacha Mwita ◽  
Brian Godman ◽  
Tonya M Esterhuizen
Keyword(s):  
Type 2 Diabetes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Secondary Data ◽  
Diabetes Clinic ◽  
Cholesterol Levels ◽  
Patients With Diabetes ◽  
Statin Prescription ◽  
Evidence Based Guideline

Abstract Background There is evidence of statin benefit among patients with diabetes regardless of their cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. Methods The study was a secondary data analysis of 374 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescription. Results Overall, 356 (95.2%) participants were eligible for a statin prescription. Clinicians prescribed statins in 162 (45.5%%; 95% confidence interval [CI]: 40.4% - 50.7%)) of eligible participants, and only one (5.5%) ineligible participant. The probability of statin prescription was high in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17 - 1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00 - 1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06 - 1.74). Conclusion Most patients with type 2 diabetes are not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescription. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations. Key words: statin, type 2 diabetes mellitus, prescription and Botswana

scholarly journals Statin prescription among patients with type 2 diabetes in Botswana: findings and implications

2019 ◽  
Author(s):  
Julius Chacha Mwita ◽  
Brian Godman ◽  
Tonya M Esterhuizen
Keyword(s):  
Type 2 Diabetes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Secondary Data ◽  
Diabetes Clinic ◽  
Cholesterol Levels ◽  
Patients With Diabetes ◽  
Statin Prescription ◽  
Evidence Based Guideline

Abstract Background There is evidence of statin benefit among patients with diabetes regardless of their cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. Methods The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescription. Results Overall, 477(95.4%) participants were eligible for statin prescription. Clinicians prescribed statins in 217 (45.5%%) of eligible participants, and only one(4.4%) ineligible participant. The probability of statin prescription was high in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17-1.89), increasing duration of diabetes(RR: 1.01; 95%CI 1.00-1.03) and the presence of chronic kidney disease(RR: 1.35; 95%CI: 1.06-1.74). Conclusion Most patients with type 2 diabetes in Gaborone are not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescription. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations.

scholarly journals Statin prescription among patients with type 2 diabetes in Botswana: findings and implications

2020 ◽  
Author(s):  
Julius Chacha Mwita ◽  
Brian Godman ◽  
Tonya M Esterhuizen
Keyword(s):  
Type 2 Diabetes ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Secondary Data ◽  
Diabetes Clinic ◽  
Cholesterol Levels ◽  
Patients With Diabetes ◽  
Statin Prescription ◽  
Evidence Based Guideline

Abstract Background There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. Methods The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescriptions. Results Overall, 477 (95.4%) participants were eligible for a statin prescription. Clinicians prescribed statins in 217 (45.5%) of eligible participants, and only one (4.4%) ineligible participant. The probability of a statin prescription was higher in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17-1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00-1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06-1.74). Conclusion A large proportion with type 2 diabetes in Gaborone is not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescriptions. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations. Keywords: statin, type 2 diabetes mellitus, prescription and Botswana

Aktivitas Antihiperkolesterolemia Ekstrak Etanol Daun Stevia Rebaudiana Bertoni Pada Tikus Putih Jantan

2020 ◽  
Vol 2 (1) ◽  
pp. 11-20
Author(s):  
Meta Kartika Untari ◽  
Ganet Elo Pramukantoro
Keyword(s):  
Total Cholesterol ◽  
Total Cholesterol Level ◽  
Density Lipoprotein ◽  
Stevia Rebaudiana ◽  
Negative Control ◽  
Stevia Rebaudiana Bertoni ◽  
Cholesterol Levels ◽  
Water Solvent ◽  
White Rats ◽  
Group I

Hypercholesterolemia is a state of increased levels of LDL (Low Density Lipoprotein) and total cholesterol in the plasma. Stevia leaves have benefits to overcome hypercholesterolemia. The aimed of this study was to obtain ethanol extracts of Stevia rebaudiana Bertoni leaves which have activity to reduce total cholesterol levels in patients with hypercholesterolemia with effective doses. The method that will be carried out to achieve this goal was to make extracts by maceration of Stevia rebaudiana Bertoni leaf powder using a water solvent for 5 days. Testing antihypercholesterolemia activity by giving treatment to 20 male white rats. Rats were divided into 5 treatment groups. Group I was negative control, II was simvastatin control, III extract was 30 mg / 200 g BW, IV extract was 60 mg / 200 g BW, V extract was 120 mg / 200 g BW. The mice were induced by propylthiouracil 12.5 mg / day and high-fat feed for 21 days, after which the rats were given the test for 14 days. Cholesterol levels were measured on days 0, 21st and 28th. The method of determining cholesterol levels uses the Easy Touch tool. On the 35th day, a total cholesterol level was examined and data analysis was performed. The results showed that the ethanol extract of stevia leaves had antihypercholesterolemia activity, extract dose of 30 mg / 200 g BW had antihypercholesterolemia activity which was equivalent to simvastatin.

scholarly journals Genetic variation of RNF145 gene and blood lipid levels in Xinjiang population, China

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jing Ming ◽  
Xian Wei ◽  
Min Han ◽  
Dilare Adi ◽  
Jialin Abuzhalihan ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Ring Finger ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipid Profiles ◽  
Cholesterol Levels ◽  
General Linear Model Analysis ◽  
Confounding Variables ◽  
Before And After ◽  
Detection Response

AbstractDyslipidemia is one of the main risk factors for coronary heart disease (CHD). The E3 ubiquitin ligase which is encoded by the ring finger protein 145 (RNF145) gene is very important in the mediation of cholesterol synthesis and effectively treats hypercholesterolemia. Thus, the purpose of the present research is to investigate the connection between the polymorphism of the RNF145 gene and cholesterol levels in the populations in Xinjiang, China. A total of 1396 participants (Male: 628, Female: 768) were included in this study for genetic analysis of RNF145 gene, and we used the modified multiple connection detection response (iMLDR) technology to label two SNPs (rs17056583, rs12188266) of RNF145 genotyping. The relationship between the genotypes and the lipid profiles was analyzed with general linear model analysis after adjusting confounding variables. Through the analysis of the two SNPs in RNF145 gene, we discovered that both rs17056583 and rs12188266 were related to total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations (All P < 0.001). In addition, the association of rs17056583 and rs12188266 with lipid profiles concentrations is still statistically significant after multivariate adjustment of sex, age, smoking, obesity, drinking, diabetes, hypertension and lipid profiles. Meanwhile, we also found that rs17056583 was associated with high triglycerides concentrations before and after adjustment (All P < 0.001). Our study shows that both rs17056583 and rs12188266 SNPs of RNP145 gene are related to TC and LDL-C concentrations in Xinjiang population.

scholarly journals Impact of supervised beego, a traditional Chinese water-only fasting, on thrombosis and haemostasis

2021 ◽  
pp. bmjnph-2020-000183
Author(s):  
Yixuan Fang ◽  
Yue Gu ◽  
Chen Zhao ◽  
Yaqi Lv ◽  
Jiawei Qian ◽  
...  
Keyword(s):  
Biological Effects ◽  
Selective Reduction ◽  
Coagulation Factors ◽  
Normal Diet ◽  
Non Invasive ◽  
Cholesterol Levels ◽  
Thrombosis Risk ◽  
Abdominal Breathing ◽  
Mediated Reduction ◽  
Platelet Formation

Beego is a traditional Chinese complete water-only fasting practice initially developed for spiritual purposes, later extending to physical fitness purposes. Beego notably includes a psychological induction component that includes meditation and abdominal breathing, light body exercise and ends with a specific gradual refeeding program before returning to a normal diet. Beego has regained its popularity in recent decades in China as a strategy for helping people in subhealthy conditions or with metabolic syndrome, but we are unaware of any studies examining the biological effects of this practice. To address this, we here performed a longitudinal study of beego comprising fasting (7 and 14 day cohorts) and a 7-day programmed refeeding phase. In addition to detecting improvements in cardiovascular physiology and selective reduction of blood pressure in hypertensive subjects, we observed that beego decreased blood triacylglycerol (TG) selectively in TG-high subjects and increased cholesterol in all subjects during fasting; however, the cholesterol levels were normalised after completion of the refeeding program. Strikingly, beego reduced platelet formation, activation, aggregation and degranulation, resulting in an alleviated thrombosis risk, yet maintained haemostasis by sustaining levels of coagulation factors and other haemostatic proteins. Mechanistically, we speculate that downregulation of G6B and MYL9 may influence the observed beego-mediated reduction in platelets. Fundamentally, our study supports that supervised beego reduces thrombosis risk without compromising haemostasis capacity. Moreover, our results support that beego under medical supervision can be implemented as non-invasive intervention for reducing thrombosis risk, and suggest several lines of intriguing inquiry for future studies about this fasting practice (http://www.chictr.org.cn/index.aspx, number, ChiCTR1900027451).

Sign in / Sign up

Export Citation Format

Share Document